

**High-Cost US Drugs: A Tale of Unhealthy Markets**  
**David Wohlever Sánchez, Jackie Xu, and Qiang Zhang**  
**Duke University**

**Bibliography**

**Personal Interviews**

Drew, D. (2017) Interviewed by David Wohlever Sánchez, Jackie Xu, and Qiang Zhang.  
[Video call] 9 February.

Nicholson, T. (2017) Interviewed by Jackie Xu. [In person] 26 January.

Pearson, H. (2017) Interviewed by Qiang Zhang. [email] 15 February.

Reynolds, C. (2017) Interviewed by Qiang Zhang. [In person] 9 February.

Ridley, D. (2017) Interviewed by Jackie Xu. [In person] 2 February.

Schulman, K. (2017) Interviewed by David Wohlever Sánchez, Jackie Xu, and Qiang Zhang.  
[In person] 26 January.

Yohai, S. (2017) Interviewed by Jackie Xu, Qiang Zhang. [Video call] 9 February.

**Primary Sources**

Cystic Fibrosis Foundation, Public Policy Inquiries. (2017). *Response to Inquiry from CFF.org regarding cystic fibrosis drug pricing*. [email].

*Important Contract Information Regarding MedImpact's Pharmacy Networks*. (2012) SI. United States, MedImpact.

**Journal Publications / Organizational Publications**

Ault, A. (2017). *Specialty drug demand is inelastic*. (Brief article). [online] Highbeam. Available at: <https://www.highbeam.com/doc/1G1-155027093.html> [Accessed 13 Feb. 2017].

Engelberg, A. and Kesselheim, A. (2016). *Use the Bayh-Dole Act to lower drug prices for government healthcare programs*. [online] Available at: <http://www.nature.com/nm/journal/v22/n6/full/nm0616-576.html> [Accessed 6 Feb. 2017].

- Gabrielli, A. and Layon, N. (2016). The Tragedy of the Commons – Drug Shortages and Our Patients' Health. *The American Journal of Medicine*, 129(12), pp.1237–1238.
- Glickman, S. and Rasiel, E. (2006). A Portfolio Model of Drug Development for Tuberculosis. *Science*, 311, pp.1246-1247.
- Halpenny, G. (2016). High Drug Prices Hurt Everyone. *ACS Medicinal Chemistry Letters*, 7, pp.544-546.
- Hirsch, B., Balu, S. and Schulman, K. (2014). The Impact of Specialty Pharmaceuticals As Drivers Of Health Care Costs. *Health Affairs*, 33(10), pp.1714-1720.
- Hotez, P. (2008). *Neglected Infections of Poverty in the United States of America*. [online] PLOS: Neglected Tropical Diseases. Available at: <http://dx.doi.org/10.1371/journal.pntd.0000256> [Accessed 13 Jan. 2017].
- Kesselheim, A. (2017). The High Cost of Prescription Drugs in the United States Origins and Prospects for Reform. *JAMA*, 316(8).
- Kyle, M., Allsbrook, J. and Schulman, K. (n.d.). Does Reimportation Reduce Price Differences for Prescription Drugs? Lessons from the European Union. *Health Research and Educational Trust*.
- Nice.org.uk. (2017). *NICE / The National Institute for Health and Care Excellence*. [online] Available at: <https://www.nice.org.uk/> [Accessed 8 Feb. 2017].
- Schulman, K. (2015). Options to Promote Competitive Generics Markets in the United States. *JAMA*, pp. E1-E2.
- Schulman, K. and Warraich, H. (2016). Health Care Tax Inversions- Robbing Both Peter and Paul. *New England Journal of Medicine*, 374(11), pp.1005-1007.
- Stoptb. (2017). *Stop TB Partnership | Global Drug Facility (GDF) - The Bedaquiline Donation Program*. [online] Available at: <http://www.stoptb.org/gdf/drugsupply/bedaquilineDonation.asp> [Accessed 6 Jan. 2017].
- Thomas, J. (2016). March-In Rights Under the Bayh-Dole Act. *Congressional Research Service*. [online] Available at: <https://fas.org/sgp/crs/misc/R44597.pdf> [Accessed 13 Jan. 2017].
- Universities Allied for Essential Medicines. (2016). *About UAEM – Universities Allied for Essential Medicines- UC Berkeley*. [online] Available at:

<https://uaem.berkeley.edu/about-uaem/> [Accessed 10 Jan. 2017].

Valverde, A., Reed, S. and Schulman, K. (2014). Proposed 'Grant-And-Access' Program With Price Caps Could Stimulate Development Of Drugs For Very Rare Diseases. *Health Affairs*, 11(31), pp. 2528-2535.

### **Websites**

Bizjournals.com. (2014). *Valeant Pharma CEO commits \$30M to Duke University*. [online]

Available at:

<http://www.bizjournals.com/triangle/news/2014/06/03/valeant-pharma-ceo-commits-30m-to-duke-university.html> [Accessed 13 Jan. 2017].

Boston Business Journal. (2010). *Harvard, Sanofi-aventis in collaboration*. [online] Available at:

<http://www.bizjournals.com/boston/news/2010/10/18/harvard-and-sanofi-aventis-in.htm> [Accessed 10 Feb. 2017].

Consumer Reports. (2016). *Is There a Cure for High Drug Prices?*. [online] Available at:

<http://www.consumerreports.org/drugs/cure-for-high-drug-prices/> [Accessed 13 Jan. 2017].

Executive and Continuing Professional Education. (2016). *Snapshot of the American Pharmaceutical Industry*. [online] Available at:

<https://www.hsph.harvard.edu/ecpe/snapshot-of-the-american-pharmaceutical-industry/> [Accessed 14 Feb. 2017].

Freudenheim, M. (2006). *A Windfall From Shifts to Medicare*. [online] Nytimes. Available at:

[http://www.nytimes.com/2006/07/18/business/18place.html?\\_r=1&oref=slogin](http://www.nytimes.com/2006/07/18/business/18place.html?_r=1&oref=slogin) [Accessed 7 Feb. 2017].

Kertscher, T. (2012). *Uncle Sam barred from bargaining Medicare drug prices, Senate candidate*

*Tammy Baldwin says, blaming rival Tommy Thompson*. [online] politifact. Available at: <http://www.politifact.com/wisconsin/statements/2012/sep/04/tammy-baldwin/uncle-sam-barred-bargaining-medicare-drug-prices-s/> [Accessed 9 Jan. 2017].

Langreth, M. (2015). *How Gilead Priced Its \$20 Billion Blockbuster*. [online] Bloomberg.com.

Available at:

<https://www.bloomberg.com/news/articles/2015-12-10/behind-the-1-000-pill-a-formula-for-profits-inside-gilead> [Accessed 13 Jan. 2017].

Los Angeles Times. (2016). *UCLA will get hundreds of millions for rights to prostate cancer*

- drug*. [online] Available at:  
<http://www.latimes.com/local/education/la-me-ucla-drug-royalties-20160304-story.html>  
[Accessed 17 Jan. 2017].
- Lyman, S. (2011). *Pharma-Academic Alliances: What the Numbers Don't Tell You* | Xconomy. [online] Xconomy. Available at:  
<http://www.xconomy.com/seattle/2011/05/10/pharma-academic-alliances-what-the-numbers-dont-tell-you/#> [Accessed 25 Jan. 2017].
- Meyer, H. (2016). *Despite outrage, no quick fix for Rx price spikes*. [online] Modern Healthcare. Available at:  
<http://www.modernhealthcare.com/article/20161001/MAGAZINE/310019988>  
[Accessed 11 Jan. 2017].
- Newsweek. (2014). *The Hypocritical Oath*. [online] Available at:  
<http://www.newsweek.com/2014/05/30/sunshine-act-will-publicize-big-pharmas-undue-influence-doctors-251736.html> [Accessed 13 Jan. 2017].
- NPR.org. (2015). *Price Soars For Key Weapon Against Heroin Overdoses*. [online] Available at:  
<http://www.npr.org/sections/health-shots/2015/09/10/439219409/naloxone-price-soars-key-weapon-against-heroin-overdoses> [Accessed 22 Dec. 2016].
- O'Brien, E. (2015). *Why drug prices remain insanely high and 6 things you can do to save*. [online] MarketWatch. Available at:  
<http://www.marketwatch.com/story/six-tips-for-fighting-rising-prescription-drug-costs-2015-09-15> [Accessed 7 Jan. 2017].
- Phil my Pockets. (n.d.). *Spread Pricing*. [online] Available at:  
<http://whorunmydrugplan.com/index.php/pharm-spread-pricing> [Accessed 12 Feb. 2017].
- PhrMA Code. (2017). *Code on interactions with health care professionals*. [online] PhrMA. Available at:  
<http://www.phrma.org/codes-and-guidelines/code-on-interactions-with-health-care-professionals> [Accessed 8 Feb. 2017].
- Pociask, S. (2012). *An Analysis of Market Power in the PBM Market - The American Consumer Institute*. [online] The American Consumer Institute. Available at:  
<http://www.theamericanconsumer.org/2012/02/an-analysis-of-market-power-in-the-pbm-market/> [Accessed 6 Feb. 2017].

Politics, T. (2016). *Lobbying Spending Database / OpenSecrets*. [online] Opensecrets.org. Available at: <https://www.opensecrets.org/lobby/top.php?indexType=i&showYear=2016> [Accessed 2 Jan. 2017].

Pollack, A. (2015). *Drug Goes From \$13.50 a Tablet to \$750, Overnight*. [online] Nytimes.com. Available at: <https://www.nytimes.com/2015/09/21/business/a-huge-overnight-increase-in-a-drugs-price-raises-protests.html> [Accessed 7 Feb. 2017].

Pollack, A. (2017). *Deal by Cystic Fibrosis Foundation Raises Cash and Some Concern*. [online] Nytimes.com. Available at: [https://www.nytimes.com/2014/11/19/business/for-cystic-fibrosis-foundation-venture-yields-windfall-in-hope-and-cash.html?\\_r=0](https://www.nytimes.com/2014/11/19/business/for-cystic-fibrosis-foundation-venture-yields-windfall-in-hope-and-cash.html?_r=0) [Accessed 9 Feb. 2017].

Raps.org. (2016). *More Competition: Senator Proposes New Priority Reviews for Some Generics, New Voucher Program / RAPS*. [online] Available at: <http://raps.org/Regulatory-Focus/News/2016/03/03/24466/More-Competition-Senator-Proposes-New-Priority-Reviews-for-Some-Generics-New-Voucher-Program/> [Accessed 6 Feb. 2017].

Swanson, A. (2015). 'Big pharmaceutical companies are spending far more on marketing than research', *Washington Post*. Available at: <https://www.washingtonpost.com/news/wonk/wp/2015/02/11/big-pharmaceutical-companies-are-spending-far-more-on-marketing-than-research/> [Accessed: 26 Feb. 2017].

Thomas, K. (2016). *20 States Accuse Generic Drug Companies of Price Fixing*. [online] Nytimes.com. Available at: <https://www.nytimes.com/2016/12/15/business/generic-drug-price-lawsuit-teva-mylan.html> [Accessed 11 Jan. 2017].

Watanabe, T. (2016). *UCLA will get hundreds of millions for rights to prostate cancer drug*. [online] latimes.com. Available at: <http://www.latimes.com/local/education/la-me-ucla-drug-royalties-20160304-story.html> [Accessed 9 Feb. 2017].

WIRE, B. (2016). *Patient Advocacy Groups Launch Joint Effort to Ensure Presidential Candidates Address Immediate Solutions to Lower Drug Costs at Next Debate*. [online] Businesswire.com. Available at: <http://www.businesswire.com/news/home/20161005005867/en/Patient-Advocacy-Groups-Launch-Joint-Effort-Ensure> [Accessed 10 Feb. 2017].

Zimmerman, B. (2017). *67% of patient advocacy groups receive funding from for-profit companies*. [online] Beckershospitalreview.com. Available at: <http://www.beckershospitalreview.com/patient-engagement/67-of-patient-advocacy-groups-receive-funding-from-for-profit-companies.html> [Accessed 10 Feb. 2017].